Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Prokopios Argyris"'
Publikováno v:
Acta Stomatologica Croatica, Vol 51, Iss 2, Pp 152-156 (2017)
Background: Myoepitheliomas are uncommon salivary gland neoplasms consisting entirely or predominantly of cells with myoepithelial phenotype. They commonly involve the parotid gland and the minor salivary glands of the palate. Aim: A case of plasmacy
Externí odkaz:
https://doaj.org/article/910ce2463b0244a0b54bd3f748c84c27
Autor:
Jordan Naumann, Prokopios Argyris, Michael Carpenter, Harshita Gupta, Yanjun Chen, Nuri Alpay Temiz, Yufan Zhou, Cameron Durfee, Joshua Proehl, Brenda Koniar, Silvestro Conticello, David Largaespada, William Brown, Hideki Aihara, Rachel Vogel, Reuben Harris
Although the APOBEC3 family of single-stranded DNA cytosine deaminases are well-known as antiviral factors, these enzymes are rapidly gaining attention as prominent sources of mutation in cancer. APOBEC3 signature single base substitutions, C-to-T an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70506454ee7ab01083752c19d7ebe159
https://doi.org/10.20944/preprints202305.0072.v1
https://doi.org/10.20944/preprints202305.0072.v1
Autor:
Dr. Prokopios Argyris, Mr. Dan Ho, Mr. Matthew C. Jarvis, Mr. Peter E. Wilkinson, Dr. Mohammed N. Islam, Dr. Indraneel Bhattacharyya, Prof. Rajaram Gopalakrishnan, Dr. Ioannis G. Koutlas, Dr. Alessio Giubellino, Prof. Reuben S. Harris
Publikováno v:
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 133:e128
Publikováno v:
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 133:e141
Autor:
Dr. Prokopios Argyris, Mr. Peter E. Wilkinson, Mr. Matthew C. Jarvis, Dr. Kelly R. Magliocca, Dr. Mihir R. Patel, Prof. Rajaram Gopalakrishnan, Prof. Reuben S. Harris
Publikováno v:
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 133:e145
Publikováno v:
Cancer Research. 82:P5-01
Background: Tumor mutation loads are a strong predictor of immunotherapy benefit. This is evidenced by studies on skin, lung, and colon cancer, where well-defined processes elicit high mutation burdens and checkpoint therapies often provoke strong an